Xuefeng Yu, CanSino Biologics CEO (Imaginechina via AP Images)

Q&A: Can in­haled vac­cines mount come­back for one-time leader in Chi­na's Covid race?

SAN FRAN­CIS­CO — In the still-un­fold­ing chron­i­cle of Covid-19 vac­cine his­to­ry, March 16, 2020 might bear an en­try on how the NIH dosed the first vol­un­teer with Mod­er­na’s mR­NA vac­cine. Much less re­mem­bered, though, is the fact that on the same day, a then-11-year-old Chi­nese vac­cine mak­er re­ceived the green­light from reg­u­la­tors in Chi­na to be­gin its own first-in-hu­man tri­al for an ade­n­ovi­ral vec­tor-based shot.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.